COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of Allo-501A and Anti0CD19 Allogeneic CAR-T Cell Therapy, and ALLO-647, an Anti CD52 Monoclonal Antibody in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Protocol No
ALLOGENE-ALLO-501A-201
Principal Investigator
Mehdi Hamadani
Phase
I
Summary
The goals of this study are to 1) test the safety of the cell therapy ALLO-501A, and 2) see how well ALLO-501A treats your disease when given after a lymphodepletion regimen containing ALLO-647 along with the chemotherapy agents fludarabine (flu) and cyclophosphamide (cy).
Description
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR-T Cells in Adults with rr LBCL
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL